GRI Stock Summary and Trading Ideas (Gri Bio | NASDAQ:GRI)

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Gri Bio trades on the NASDAQ stock market under the symbol GRI.

As of March 13, 2026, GRI stock price declined to $2.54 with 60,440 million shares trading.

GRI has a beta of 5.36, meaning it tends to be more sensitive to market movements. GRI has a correlation of 0.19 to the broad based SPY ETF.

GRI has a market cap of $3.67 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that GRI belongs to (by Net Assets): VXF.

GRI has underperformed the market in the last year with a return of -98.5%, while the SPY ETF gained +21.4%. In the last 3 month period, GRI fell short of the market, returning -82.8%, while SPY returned -2.6%. However, in the most recent 2 weeks GRI has outperformed the stock market by returning -0.4%, while SPY returned -3.5%.

GRI support price is $2.74 and resistance is $3.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRI shares will trade within this expected range on the day.